Fintel · Aug 28, 2026
AD
NYSE · ADCT
ADC Therapeutics S.A.
Healthcare · Biotechnology
$1.36
Up+$0.04 (+3.03%)
Updated Sep 8, 2026, 9:58 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 507.9M
- P/E ratio
- -3.35
- Dividend yield
- 0.00%
- 52-week range
- $0.78 – $4.98
- Volume
- 1.48M
- Avg. volume
- 1.16M
Price performance
ADCT price history
1M range · 20 trading sessions · Daily adjusted prices
ADCT closed at $1.36 after 20 trading sessions, up 20.35% for the selected period.
- Last close
- $1.36
- Period change
- +20.35%
- Period low
- $0.96
- Period high
- $1.36
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $1.30 | $1.37 | $1.30 | $1.36 | 1.48M |
| Sep 3, 2026 | $1.32 | $1.37 | $1.30 | $1.32 | 2.77M |
| Sep 2, 2026 | $1.23 | $1.35 | $1.23 | $1.32 | 1.96M |
| Sep 1, 2026 | $1.15 | $1.24 | $1.14 | $1.24 | 1.15M |
| Aug 31, 2026 | $1.13 | $1.19 | $1.125 | $1.17 | 1.25M |
| Aug 28, 2026 | $1.11 | $1.17 | $1.07 | $1.14 | 2.58M |
| Aug 27, 2026 | $1.05 | $1.14 | $1.05 | $1.12 | 1.4M |
| Aug 26, 2026 | $1.04 | $1.075 | $1.01 | $1.05 | 1.95M |
| Aug 25, 2026 | $0.9755 | $1.05 | $0.96 | $1.04 | 3.93M |
| Aug 24, 2026 | $0.99 | $1.00 | $0.9514 | $0.9651 | 640.51K |
| Aug 21, 2026 | $0.974 | $1.00 | $0.97 | $0.9966 | 1.09M |
| Aug 20, 2026 | $1.02 | $1.04 | $0.9497 | $0.9601 | 2.42M |
| Aug 19, 2026 | $1.05 | $1.09 | $1.015 | $1.04 | 1.9M |
| Aug 18, 2026 | $1.05 | $1.08 | $1.03 | $1.03 | 3.44M |
| Aug 17, 2026 | $0.99 | $1.10 | $0.95 | $1.10 | 3.73M |
| Aug 14, 2026 | $1.02 | $1.04 | $1.00 | $1.01 | 1.35M |
| Aug 13, 2026 | $1.07 | $1.10 | $0.9393 | $1.05 | 2.19M |
| Aug 12, 2026 | $1.20 | $1.23 | $1.155 | $1.23 | 563.56K |
| Aug 11, 2026 | $1.11 | $1.20 | $1.11 | $1.18 | 664.34K |
| Aug 10, 2026 | $1.14 | $1.17 | $1.12 | $1.13 | 569.55K |
Latest ADCT news
The latest Smart Investors Daily articles mentioning ADCT.
Stock researchCompany · Overview
ADCT research
Overview
Company profile and research snapshot.
Company profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Guggenheim | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 4, 2026 | RBC Capital | Sector Perform | — |
| May 5, 2026 | RBC Capital | Outperform | — |
| May 5, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 17, 2026
Guggenheim Maintains Buy on ADC Therapeutics, Lowers Price Target to $5
Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to $5.
SeekingAlpha · Aug 13, 2026
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q2 2026 Earnings Call August 13, 2026 8:30 AM EDTCompany ParticipantsNicole Riley - Head of Investor Relations & Corporate...
Benzinga · Aug 13, 2026
ADC Therapeutics Q2 2026 Earnings Call Transcript
On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
